Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 13;55(2):49.
doi: 10.3390/medicina55020049.

Ventilator-Associated Pneumonia due to Drug-Resistant Acinetobacter baumannii: Risk Factors and Mortality Relation with Resistance Profiles, and Independent Predictors of In-Hospital Mortality

Affiliations

Ventilator-Associated Pneumonia due to Drug-Resistant Acinetobacter baumannii: Risk Factors and Mortality Relation with Resistance Profiles, and Independent Predictors of In-Hospital Mortality

Aušra Čiginskienė et al. Medicina (Kaunas). .

Abstract

Background and objectives: High mortality and healthcare costs area associated with ventilator-associated pneumonia (VAP) due to Acinetobacter baumannii (A. baumannii). The data concerning the link between multidrug-resistance of A. baumannii strains and outcomes remains controversial. Therefore, we aimed to identify the relation of risk factors for ventilator-associated pneumonia (VAP) and mortality with the drug resistance profiles of Acinetobacter baumannii (A. baumannii) and independent predictors of in-hospital mortality. Methods: A retrospective ongoing cohort study of 60 patients that were treated for VAP due to drug-resistant A. baumannii in medical-surgical intensive care units (ICU) over a two-year period was conducted. Results: The proportions of multidrug-resistant (MDR), extensively drug-resistant (XDR), and potentially pandrug-resistant (pPDR) A. baumannii were 13.3%, 68.3%, and 18.3%, respectively. The SAPS II scores on ICU admission were 42.6, 48.7, and 49 (p = 0.048); hospital length of stay (LOS) prior to ICU was 0, one, and two days (p = 0.036), prior to mechanical ventilation (MV)-0, 0, and three days (p = 0.013), and carbapenem use prior to VAP-50%, 29.3%, and 18.2% (p = 0.036), respectively. The overall in-hospital mortality rate was 63.3%. In MDR, XDR, and pPDR A. baumannii VAP groups, it was 62.5%, 61.3%, and 72.7% (p = 0.772), respectively. Binary logistic regression analysis showed that female gender (95% OR 5.26; CI: 1.21⁻22.83), SOFA score on ICU admission (95% OR 1.28; CI: 1.06⁻1.53), and RBC transfusion (95% OR 5.98; CI: 1.41⁻25.27) were all independent predictors of in-hospital mortality. Conclusions: The VAP risk factors: higher SAPS II score, increased hospital LOS prior to ICU, and MV were related to the higher resistance profile of A. baumannii. Carbapenem use was found to be associated with the risk of MDR A. baumannii VAP. Mortality due to drug-resistant A. baumannii VAP was high, but it was not associated with the A. baumannii resistance profile. Female gender, SOFA score, and RBC transfusion were found to be independent predictors of in-hospital mortality.

Keywords: A. baumannii; drug resistance; mortality; predictors; ventilator-associated pneumonia (VAP).

PubMed Disclaimer

Conflict of interest statement

Rello served in the speaker’s bureau or consultant for Pfizer, Novartis, ROCHE. The remaining authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
The relationship between A. baumannii drug resistance profile and mortality. Abbreviations: MDR—multidrug-resistant, XDR—extensively drug-resistant, pPDR—potentially pandrug-resistant, AcB—A. baumannii, and VAP—ventilator-associated pneumonia.
Figure 2
Figure 2
Receiver operating characteristic (ROC) curves for predicting in-hospital mortality according to Simplified Acute Physiology Score (SAPS II), Acute Physiology and Chronic Health Evaluation (APACHE) II, and Sequential Organ Failure Assessment (SOFA) scores at intensive care unit (ICU) admission.

References

    1. American Thoracic Society. Infectious Diseases Society of America Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005;171:388–416. doi: 10.1164/rccm.200405-644ST. - DOI - PubMed
    1. Ozgur E., Horasan E., Karaca K., Ersoz G., Atis S.N., Kaya A. Ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii: Risk factors, clinical features, and outcomes. Am. J. Infect. Control. 2014;42:206–208. doi: 10.1016/j.ajic.2013.09.003. - DOI - PubMed
    1. Li Y.J., Pan C.Z., Fang C.Q., Zhao Z.X., Chen H.L., Guo P.H., Zhao Z.W. Pneumonia caused by extensive drug-resistant Acinetobacter baumannii among hospitalized patients: Genetic relationships, risk factors and mortality. BMC Infect. Dis. 2017;17:371. doi: 10.1186/s12879-017-2471-0. - DOI - PMC - PubMed
    1. Guillamet C.V., Kollef M.H. Acinetobacter pneumonia: Improving outcomes with early identification and appropriate therapy. Clin. Infect. Dis. 2018;67:1455–1462. doi: 10.1093/cid/ciy375. - DOI - PubMed
    1. Niederman M.S., Kollef M.H. The road forward in the management of Acinetobacter infections in ICU. Intensive Care Med. 2015;41:2207–2209. doi: 10.1007/s00134-015-4108-3. - DOI - PubMed

MeSH terms

LinkOut - more resources